Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis

. 2022 May ; 62 (5) : 624-633.

Jazyk angličtina Země Spojené státy americké Médium print

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/pmid35593783

OBJECTIVE: To assess the long-term efficacy and safety of erenumab in the subgroup of patients with chronic migraine (CM) in whom prior preventive treatments had failed (TF) (≥1, ≥2, and ≥3 TF medication categories) and never failed (preventive naïve or prior preventive treatments had not failed), using the data from a 52-week, open-label treatment period (OLTP) of the parent study. BACKGROUND: Erenumab is a fully human monoclonal antibody that selectively binds to and inhibits the canonical calcitonin gene-related peptide receptor. There are limited long-term data evaluating the efficacy and safety of erenumab in patients with CM in whom prior preventive treatments had failed. METHODS: Patients who had completed the 12-week double-blind treatment period (DBTP) in the parent study were eligible to participate in the 52-week OLTP, during which they received erenumab every 4 weeks. The TF subgroups (≥1, ≥2, and ≥3 TF medication categories) were not mutually exclusive; patients in whom prior preventive treatments from ≥3 medication categories had failed were also counted in the ≥2 and ≥1 medication categories. Endpoints included monthly migraine days (MMD), monthly acute migraine-specific medication days (MSMD), achievement of ≥50%, ≥75%, and 100% reduction from baseline in MMD, and exposure-adjusted patient incidence rates of adverse events (AEs; per 100 patient-years). RESULTS: Erenumab treatment provided sustained mean reductions in MMD and MSMD relative to the parent study baseline throughout the 52 weeks of the OLTP across all TF subgroups. At Week 52, the mean MMD change was -8.6 (SD 6.6) (baseline: 18.4 [SD 4.5] days) in the ≥1 TF subgroup. A post hoc completer analysis (52 weeks [OLTP] erenumab) showed that compared with erenumab 70 mg, the 140 mg dose was associated with numerically greater reductions in the mean MMD (Week 40: -8.6 and -7.2 days; Week 52: -9.7 and -7.9 days [≥1 TF subgroup]) and a higher proportion of patients achieved ≥50%, ≥75%, and 100% response thresholds across all subgroups at Weeks 40 and 52. Overall the exposure-adjusted patient incidence rates of AEs did not increase during the OLTP versus the DBTP (≥1 TF subgroup: 141.9/100 versus 317.9/100 patient-years), and no new safety signals occurred. CONCLUSION: The long-term treatment with erenumab was well tolerated and showed sustained efficacy in patients with CM in whom prior preventive treatments had failed, with numerically greater treatment effects for 140 mg versus 70 mg.

Zobrazit více v PubMed

Cho SJ, Song TJ, Chu MK. Treatment update of chronic migraine. Curr Pain Headache Rep. 2017;21:26. PubMed

American Headache Society . The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1‐18. PubMed

Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37:470‐485. PubMed PMC

Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine‐preventive medications among patients with chronic migraine. Cephalalgia. 2015;35:478‐488. PubMed

Shi L, Lehto SG, Zhu DXD, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene‐related peptide receptor. J Pharmacol Exp Ther. 2016;356:223‐231. PubMed

AimovigTM United States prescribing information. Accessed March 23, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf

AimovigTM Summary of product characteristics. Accessed March 23, 2022. https://www.ema.europa.eu/documents/product‐information/aimovig‐epar‐product‐information_en.pdf

Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first‐of‐its‐kind treatment specifically designed for migraine prevention. Press release, July 30, 2018. Accessed March 23, 2022. https://www.novartis.com/news/media‐releases/novartis‐marks‐new‐era‐migraine‐patients‐eu‐approval‐aimovigr‐first‐its‐kind‐treatment‐specifically‐designed‐migraine‐prevention

Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurol. 2017;16:425‐434. PubMed

Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123‐2132. PubMed

Tepper SJ, Ashina M, Reuter U, et al. Long‐term safety and efficacy of erenumab in patients with chronic migraine: results from a 52‐week, open‐label extension study. Cephalalgia. 2020;40(6):543‐553. PubMed

Ashina M, Tepper S, Brandes JL, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double‐blind, placebo‐controlled study. Cephalalgia. 2018;38:1611‐1621. PubMed

Lipton RB, Tepper SJ, Silberstein SD, et al. Reversion from chronic migraine to episodic migraine following treatment with erenumab: results of a post‐hoc analysis of a randomized, 12‐week, double‐blind study and a 52‐week, open‐label extension. Cephalalgia. 2021;41:6‐16. PubMed PMC

Reuter U, Goadsby PJ, Lanteri‐Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two‐to‐four previous preventive treatments were unsuccessful: a randomised, double‐blind, placebo‐controlled, phase 3b study. Lancet. 2018;392:2280‐2287. PubMed

Reuter U, Gaodsby PJ, Lanteri‐Minet M, et al. Long‐term efficacy and safety of erenumab: results from 64 weeks of the LIBERTY study. [IHC‐OR‐006]. Cephalalgia. 2019;39(1 Suppl);10‐11. PubMed PMC

Najít záznam

Citační ukazatele

Možnosti archivace